Company news
Cerus Corporation news in 2020
Cerus Corporation's news releases, calls and decks from 2020, newest first.
Cerus’ Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology and Hemotherapy Center Foundation (HemoMinas) in Brazil for the INTERCEPT Blood System for Platelets
December 14, 2020
Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting
December 3, 2020
Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation
November 29, 2020
Cerus Corporation Announces Record Third Quarter 2020 Results
October 28, 2020
Cerus Corporation to Release Third Quarter 2020 Financial Results on October 29, 2020
October 18, 2020
Cerus Corporation Announces Five-Year FDA Contract for the Development of Next Generation Pathogen Reduction Technology to Treat Whole Blood
October 12, 2020
Cerus Corporation Announces Schedule of Presentations at the AABB 2020 Virtual Annual Meeting
September 27, 2020
Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch
August 6, 2020
Cerus Corporation Announces Record Second Quarter 2020 Results
August 3, 2020
Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems
July 29, 2020
Cerus Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020
July 22, 2020
Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma
July 6, 2020
Cerus Corporation Celebrates World Blood Donor Day
June 11, 2020
Cerus Corporation Announces FDA PMA Supplement Submission for Pathogen-Reduced Cryoprecipitated Fibrinogen Complex
May 25, 2020
Cerus Corporation Announces First Quarter 2020 Results
May 4, 2020
Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Plasma with Alternate Plastic Disposable Kits
May 3, 2020
Cerus Corporation to Release First Quarter 2020 Financial Results on May 5, 2020
April 23, 2020
Cerus Corporation Announces Expansion of BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
April 19, 2020
Cerus Corporation Provides Update on COVID-19 Related Activities
April 5, 2020
University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma
April 1, 2020
Cerus Corporation Announces the Inclusion of Pathogen Reduction Technology in the ISBT Working Party Recommendations for the Preparation of COVID-19 Convalescent Plasma
April 1, 2020
Cerus Forms Group to Research Optimal Production of COVID-19 Convalescent Plasma
March 25, 2020
Cerus Corporation Announces Strategic Organizational Changes
March 1, 2020
Cerus Corporation Announces Record Fourth Quarter and Full Year 2019 Financial Results
February 19, 2020
U.S. Department of Defense Awards Funding for Study to Evaluate the Use of INTERCEPT Plasma in Traumatic Burn Resuscitation
February 17, 2020
Cerus Corporation to Release Fourth Quarter and Full Year 2019 Financial Results on February 20, 2020
February 11, 2020
Cerus Corporation Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
January 30, 2020
Cerus Corporation Announces Pricing of Upsized Public Offering of Common Stock
January 28, 2020
Cerus Corporation Announces Public Offering of Common Stock
January 27, 2020
Coronavirus Inactivation Reported in Recent INTERCEPT Blood System Publication in Transfusion Medicine
January 22, 2020
French Hemovigilance Report Highlights Safety and Effectiveness of INTERCEPT Platelets During First Full Year of 100% Production and Routine Use
January 20, 2020
Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2019 Product Revenue
January 12, 2020